Case An 81-year-old man presented with dizziness, fatigue and shortness of breath one day after a min-invasive neck spine surgery. The patient said the surgery had been successful, and he was able to get up and walk on the first day, but on the second day he felt dizzy, tired, and dyspnoea. He also found his two hands were swelling. He denied chest pain, unconsciousness, vomiting and other symptoms. The patient was on medication of hypertension and diabetes before the surgery, and both of his wife and son have hypertension. The patient does not smoke nor drink. After surgery, the patient was given antibiotics by venous infusion. On physical examination, the patient looked conscious, well nourished but having a big belly. His temperature was normal. His four extremities were swelling. He had jugular retention. His blood pressure was 164/83 mm Hg, heart rate was 86 bpm and respiratory rate was 24. Heart auscultation revealed no heart murmur and normal heart rhythm. Pulmonary auscultation found some moist rales at the lower part of two lungs. Chest x-ray showed his heart was boot-shaped, lungs were clear and there was a little pleural effusion in the thorax. Cervical vertebra x-ray showed that the third and fourth spine cords were fixed by steel and there was ossification of nuchal ligament. ECG was almost normal. Echocardiography showed that the internal diameter of left atrium was 50 mm at diastolic phase; the right atrium was enlarged and the left ventricular posterior wall a bit thicker; the aortic sinus and proximal ascending aorta were widened; the left ventricular ejection fraction was 66%; the diastolic function was slightly reduced. The complete blood count showed: white-cell count 6.11×109/l, neutrophil-cell count 4.22×109/l, percentage of neutrophil-cell 69.1%, red-cell count 4.24×1012, haemoglobin 125.0 g/l, haematocrit 37.6%, platelet count 136×109/l. The biochemistry test showed: serum potassium 4.1 mmol/l, serum sodium 142.0 mmol/l, serum chloride 99 mmol/l, carbon dioxide 24.0 mmol/l, serum calcium 2.53 mmol/l, creatinine 124.0 ummol/l, blood urea nitrogen 8.2 mmol/l, uric acid 527.0 umol/l. Serum brain natriuretic peptide level: 348 pg/ml. Blood glucose level: 6.88 mmol/l. The diagnosis of this patient was based on his symptoms of fatigue, and shortness of breath at rest; physical examination of jugular retention, lung rales at lower part and ankle oedema; chest x-ray of pleural effusion. These symptoms and findings indicated the patient had pulmonary congestion and systemic congestion. Though ECG was normal, echocardiography showed diastolic dysfunction, and the serum BNP level was significantly raised. Thus the patient was diagnosed as: acute heart failure, diastolic heart failure, NYHA IV, Stage C; hypertension, grade 3; type 2 diabetes mellitus; cervical spondylopathy, post mini-invasive spine surgery. The treatment included blood pressure monitoring, urinary volume monitoring and electrocardiographic monitoring. Medications included vasodilator nitrate to relief cardiac workload; loop diuretic furosemide to induce diuresis; ACE inhibitor fosinopril to control hypertension; statin atorvastatin to lower lipid level; Insulin to control glucose level. The patient stayed in hospital for 10 days and discharged with no dyspnoea and low extremity oedema, no pulmonary rales, blood pressure 139/69 mm Hg and heart rate 57 bpm. During the 3 months follow-up after discharge, the patient strictly followed doctor's written instructions on diet restriction and exercise. He measured blood pressure, heart rate and weight and then recorded the results every day. His weight maintained 81 to 82 kg. The patient took a walk four times a day and increased from 5 min each time to 15 min each time per day. His medication included diuretic, ACEI, beta-blocker, aspirin, and metformin. Furosemide has been changed to hydrochlorothiazide and maintains at 12.5 mg per day. Aspirin was 100 mg per day. Fosinopril was replaced by valsartan due to dry cough. Valsartan has been gradually up-titrated. When the patient was taking valsartan 80 mg b.i.d., his mean blood pressure was 127/67 mm Hg, but his 24-h ambulatory blood pressure monitoring showed that his night-time blood pressure was nondipping and about 80% was over 120/80 mm Hg despite of the well controlled day-time blood pressure. Then valsartan was up-titrated to 80 mg, t.i.d., and his morning supine blood pressure lowered from 155/83 mm Hg to 132/74 mm Hg and maintained at about 116/60 mm Hg during the day. Bisotolol was not up-titrated due to his relative low heart rate and diabetes. Discussion Heart failure is the leading cause of hospitalisation and mortality in developed and developing countries despite of the improvement of heart disease and longevity of population.1 It is primarily developed in the elderly population and cause big economic burden to the society. In the United States, the annual incidence of heart failure hospitalisation in patients older than 65 years is 10 per 1000. The average duration of hospitalisation is about 6 days. About 2% of hospital admission is the decompensated heart failure and rehospitalisation rate reaches 50% in 6 months after discharge. Approximately two thirds of cost attributes to the management of episodes of acute decompensated heart failure. The underlined causes of heart failure are coronary artery disease, hypertension, diabetes, metabolic syndrome and others. Though myocardial infarction accounts for 60% of heart failure, 70% of heart failure has a medical history of hypertension. Up till now, there are 40% to 50% acute decompensated heart failure has unknown causes. The poor compliance with medication or diet restriction, under controlled hypertension or diabetes, ischaemia, anaemia, diabetes, renal dysfunction, drugs such as calcium-channel blockers and nonsteroidal anti-inflammatory drugs may precipitate decompensated heart failure. In patients with hypertension, blood pressure is normally monitored at doctor's office and at patient home. The information of blood pressure may be not complete by day-time office monitoring if the patient has nondipping hypertension or nocturnal hypertension. Studies show that hypertension with nondipping pattern especially those with nondipping diastolic blood pressure contributes to congestive heart failure. The underlined mechanism could be the increased left ventricular filling pressure.2 The diagnosis of congestive heart failure is based on suspected symptoms such as shortness of breath at rest or exertion, fatigue or tiredness and oedema at ankle; typical signs on physical examination such as tachycardia, pulmonary rales, raised jugular venous pressure, peripheral oedema, cardiomegaly, abnormal murmur and hepatomegaly; specific test results such as normal or abnormal ECG, echocardiogram with left ventricular enlargement and low left ventricular ejection fraction, and elevated serum brain natriuretic peptide level. The symptoms of heart failure indicate the deficiency of blood supply of tissues and organs due to the pump failure. ECG may be normal or abnormal due to ischemia. If echocardiogram shows the left ventricular enlargement and reduced left ventricular ejection fraction, it indicates the patient has systolic heart failure; if echocardiogram shows preserved left ejection fraction but left atrium enlargement and reduced diastolic function, it indicates the patient has diastolic heart failure. Serum brain natriurectic peptide level may increase due to increased left ventricular filling pressure, when its level surpasses 100 pg/ml heart failure is considered. Elevated blood natriuretic peptide levels (BNP or NT-proBNP) help to differentiate other diseases such as COPD, pulmonary embolism and pneumonia. The exercise capacity may be evaluated by the 6 min walk test. Heart failure is currently classified into four stages: Stage A–high risks of heart failure; Stage B–abnormal cardiac structure without symptoms; Stage C–abnormal cardiac structure with symptoms; Stage D–refractory symptoms requiring specialised, advanced treatment strategies. For a patient diagnosed with heart failure, prognostic stratification of heart failure should be evaluated, as the mortality of heart failure is high, especially in elderly patients. NYHA functional classification used to be the most common standard for the severity of heart failure, however it is subjective under doctor's judgement. Symptoms, though relate to the severity of heart failure, should not be used to guide drug therapies, especially titration of ACE-inhibitors or beta-blockers. Staging classification provides objective scales to heart failure and clinical trial showed heart failure staging were associated with progressively increasing plasma BNP concentration and progressively higher 5-year mortality rates. The plasma level of natriuretic peptides is significantly related to the severity of heart failure. It is used as the surrogate marker of heart failure.3 High plasma BNP level is associated with high risk of rehospitilization and death. A plasma level of BNP>1000 pg/ml despite of optimal treatments usually indicates a poor prognosis. The treatment of chronic heart failure at stage C aims to prevent progression and cardiac events. Organising a heart failure team is effective to manage chronic heart failure patients. Education and instruction on diet, exercise, weight control and early sign of decompensation to patients should be done before dischargement or right after diagnosis of heart failure during out-patient clinic. Follow up of patients should be conducted by any possible method such as telephone and appointment. Each patient is encouraged to self care of the disease at home. Patients shall be educated at discharge that some factors may precipitate heart failure decompensation such as poor compliance with medication or dietary restriction, ischemia, hypertension, and arrhythmias. The other factors are anaemia, diabetes, renal dysfunction and medications such as calcium-channel blockers and nonsteroidal anti-inflammatory drugs. Besides education, written instruction with core content of follow up shall be provided to patients, including recommended exercise frequency, weight variation, medication and up-titration. During the follow-up, a well designed checklist including blood pressure, blood glucose, heart rate, weight, exercise frequency and time, change of medications or therapy, and careplayer telephone number is recommended to be provided to heart failure patients for his/her selfcare management. Detailed and insistent records help doctor to understand the patient process thoroughly. Early detection of congestion is critical for treatment adjustment so as to prevent symptoms and rehospitalization. Beside daily weight monitoring by patients themselves, an intrathoracic impedance device is under investigated and promising results show that the device will be superior to daily weight monitoring to alarm the haemodynamic congestion of heart failure.4 Similarly, monitoring of serum BNP level is also an effective approach in clinic to predict the episodes of worsening of heart failure.